Mercer Global Advisors
SPRY icon

Mercer Global Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Mercer Global Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.6K Buy
+7,190
New +$61.8K ﹤0.01% 4217

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mercer Global Advisors's SPRY Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 7,190 shares worth $57.6K. The stake represents ﹤0.01% of the portfolio and ranks #4217 among its holdings.

192 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Mercer Global Advisors held 7,190 shares of ARS Pharmaceuticals worth $57.6K as of Q2 2026.
  • ARS Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4217 holding.
  • 192 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.